Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | HRH1 | P35367 | 2/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30672504 | 0.87 | — | — | |
| SCHEMBL173147 | 0.87 | — | — | |
| SCHEMBL20927237 | 0.86 | TDP1 (0.54) | TDP1L3MBTL1TBXAS1CHRNA7HRH4 | |
| SCHEMBL135032 | 0.85 | TDP1 (1.00) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| Ammonia Solution, Strong SCHEMBL2797706 | 0.85 | TDP1 (0.71) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| Bromide SCHEMBL14801915 | 0.85 | TDP1 (0.71) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL11563304 | 0.85 | TDP1 (0.71) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL25381701 | 0.84 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL25382598 | 0.84 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| Bromide SCHEMBL15822430 | 0.84 | TDP1 (0.96) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | TDP1 4110/4885L3MBTL1 4128/4885HRH1 1832/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | TDP1 4110/4885L3MBTL1 4128/4885HRH1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.